Bibliografias temáticas / GB recurrence

Literatura científica selecionada sobre o tema "GB recurrence"

Autor: Grafiati

Publicado: 20 de julho de 2024

Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos

Selecione um tipo de fonte:

Índice

Artigos de revistas
Teses / dissertações
Trabalhos de conferências

Consulte a lista de atuais artigos, livros, teses, anais de congressos e outras fontes científicas relevantes para o tema "GB recurrence".

Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.

Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.

Artigos de revistas sobre o assunto "GB recurrence"

Stadlbauer, Andreas, Ilker Eyüpoglu, Michael Buchfelder, Arnd Dörfler, Max Zimmermann, Gertraud Heinz e Stefan Oberndorfer. "Vascular architecture mapping for early detection of glioblastoma recurrence". Neurosurgical Focus 47, n.º 6 (dezembro de 2019): E14. http://dx.doi.org/10.3171/2019.9.focus19613.

Texto completo da fonte

Resumo:

OBJECTIVETreatment failure and inevitable tumor recurrence are the main reasons for the poor prognosis of glioblastoma (GB). Gross-total resection at repeat craniotomy for GB recurrence improves patient overall survival but requires early and reliable detection. It is known, however, that even advanced MRI approaches have limited diagnostic performance for distinguishing tumor progression from pseudoprogression. The novel MRI technique of vascular architectural mapping (VAM) provides deeper insight into tumor microvascularity and neovascularization. In this study the authors evaluated the usefulness of VAM for the monitoring of GB patients and quantitatively analyzed the features of neovascularization of early- and progressed-stage GB recurrence.METHODSIn total, a group of 115 GB patients who received overall 374 follow-up MRI examinations after standard treatment were retrospectively evaluated in this study. The clinical routine MRI (cMRI) protocol at 3 Tesla was extended with the authors’ experimental VAM approach, requiring 2 minutes of extra time for data acquisition. Custom-made MATLAB software was used for calculation of imaging biomarker maps of macrovascular perfusion from perfusion cMRI as well as of microvascular perfusion and architecture from VAM data. Additionally, cMRI data were analyzed by two board-certified radiologists in consensus. Statistical procedures included receiver operating characteristic (ROC) analysis to determine diagnostic performances for GB recurrence detection.RESULTSOverall, cMRI showed GB recurrence in 89 patients, and in 28 of these patients recurrence was detected earlier with VAM data, by 1 (20 patients) or 2 (8 patients) follow-up examinations, than with cMRI data. The mean time difference between recurrence detection with VAM and cMRI data was 147 days. During this time period the mean tumor volume increased significantly (p < 0.001) from 9.7 to 26.8 cm3. Quantitative analysis of imaging biomarkers demonstrated microvascular but no macrovascular hyperperfusion in early GB recurrence. Therefore, ROC analysis revealed superior diagnostic performance for VAM compared with cMRI.CONCLUSIONSThis study demonstrated that the targeted assessment of microvascular features using the VAM technique provided valuable information about early neovascularization activity in recurrent GB that is complementary to perfusion cMRI and may be helpful for earlier and more precise monitoring of patients suffering from GB. This VAM approach is compatible with existing cMRI protocols. Prospective clinical trials are necessary to investigate the clinical usefulness and potential benefit of increased overall survival with the use of VAM in patients with recurrent GB.

Estilos ABNT, Harvard, Vancouver, APA, etc.

Stadlbauer, Andreas, Stefan Oberndorfer, Max Zimmermann, Bertold Renner, Michael Buchfelder, Gertraud Heinz, Arnd Doerfler, Andrea Kleindienst e Karl Roessler. "Physiologic MR imaging of the tumor microenvironment revealed switching of metabolic phenotype upon recurrence of glioblastoma in humans". Journal of Cerebral Blood Flow & Metabolism 40, n.º 3 (7 de fevereiro de 2019): 528–38. http://dx.doi.org/10.1177/0271678x19827885.

Texto completo da fonte

Resumo:

Treating recurrent glioblastoma (GB) is one of the challenges in modern neurooncology. Hypoxia, neovascularization, and energy metabolism are of crucial importance for therapy failure and recurrence. Twenty-one patients with initially untreated GB who developed recurrence were examined with a novel MRI approach for noninvasive visualization of the tumor microenvironment (TME). Imaging biomarker information about oxygen metabolism (mitochondrial oxygen tension) and neovascularization (microvascular density and type) were fused for classification of five different TME compartments: necrosis, hypoxia with/without neovascularization, oxidative phosphorylation, and glycolysis. Volume percentages of these TME compartments were compared between untreated and recurrent GB. At initial diagnosis, all 21 GB showed either the features of a glycolytic dominant phenotype with a high percentage of functional neovasculature (N = 12) or those of a necrotic/hypoxic dominant phenotype with a high percentage of defective tumor neovasculature (N = 9). At recurrence, all 21 GB revealed switching of the initial metabolic phenotype: either from the glycolytic to the necrotic/hypoxic dominant phenotype or vice-versa. A necrotic/hypoxic phenotype at recurrence was associated with a higher rate of multifocality of the recurrent lesions. Our MRI approach may be helpful for a better understanding of treatment-induced metabolic phenotype switching and for future studies developing targeted therapeutic strategies for recurrent GB.

Estilos ABNT, Harvard, Vancouver, APA, etc.

Lessi, F., M. Morelli, P. Aretini, M. Menicagli, S. Franceschi, F. Pasqualetti, C. Gambacciani, A. Di Stefano, O. Santonocito e C. M. Mazzanti. "P14.01.B Isolation and characterization of circulating tumor cells in a glioblastoma case with recurrence at distance and correlation with tumor mutational status". Neuro-Oncology 24, Supplement_2 (1 de setembro de 2022): ii82. http://dx.doi.org/10.1093/neuonc/noac174.286.

Texto completo da fonte

Resumo:

Abstract Background Circulating Tumor Cells (CTCs) are considered to be one of the important causes of tumor recurrence and distant metastasis. For many years, glioblastoma (GB) was thought to be restricted to the brain. Nevertheless, a growing body of evidence indicates that, like many other cancers, hematogenic dissemination is a reality. The absence of a procedural uniformity in literature prompted us to develop an innovative and sensitive method to obtain CTCs in GB. Our aim is to define the genetic background of single CTCs compared with the primary GB tumor and its recurrence to assess whether or not their presence in the peripheral circulation correlates with GB migration and dissemination. Material and Methods CTCs were enriched from whole blood of one patient with recurrent GB with Parsortix Cell Separation System and analysed on DEPArray system. After that, CTCs Copy Number Aberrations (CNAs) and sequencing analysis was performed to compare CTCs genetic background with the same patient’s primary and recurrence tissues, analysed by NextSeq 500 (whole exome sequencing). Results We obtained 211 mutations in common between primary and recurrence tumor. Among these, three somatic mutations (c.430 G>A in PRKCB gene, c.815 C>T in TBX1 gene and c.1554 T>G in COG5 gene) were selected to investigate their presence in recurrence CTCs. Almost all of the sorted CTCs (9/13) had at least one of the mutations tested. Conclusion In confirmation of the hypothesis, the CTCs detected in the patient's blood were actually cancer cells deriving from GB tumor.

Estilos ABNT, Harvard, Vancouver, APA, etc.

Beppu, Takaaki, Yuichi Sato, Toshiaki Sasaki, Kazunori Terasaki e Kuniaki Ogasawara. "NI-19 Use of 11C-methionine PET for decision of discontinuation of adjuvant chemotherapy with temozolomide". Neuro-Oncology Advances 2, Supplement_3 (1 de novembro de 2020): ii14. http://dx.doi.org/10.1093/noajnl/vdaa143.062.

Texto completo da fonte

Resumo:

Abstract Background: The aim was to clarify whether positron emission tomography with 11C-methyl-L-methionine (met-PET) is useful to decide on discontinuation of TMZ-adjuvant therapy in patients with residual diffuse astrocytic tumor. Methods: Subjects were 44 patients with residual tumor comprising 17 with IDH1-mutant diffuse astrocytoma (DA), 13 with IDH1-mutant anaplastic astrocytoma (AA), and 14 with IDH1-wild glioblastoma (GB). All patients received TMZ-adjuvant chemotherapy (median, 12 courses), and whether to discontinue or continue TMZ-adjuvant chemotherapy was decided on the basis of the tumor-to-normal ratio in standardized uptake value from met-PET (T/N); patients with T/N < 1.6 immediately discontinued TMZ, and patients with T/N > 1.6 were either to continued or discontinued TMZ. Progression-free survival (PFS) was compared between patients with T/N > 1.6 and T/N < 1.6 in each tumor type. Median observation period was 434 days after met-PET scanning. Results: The number of patient who underwent recurrence was 10 in DA, 7 in AA, and 11 in GB. All patients showing T/N > 1.6 underwent tumor recurrence. PFS was significantly longer in patients with T/N < 1.6 than T/N > 1.6 in DA and AA (p < 0.01 in both types), but was no significant difference between 2 groups in GB (p = 0.06). Sixteen of 17 patients (94%) in DA and AA showed recurrence from residual tumor, whereas 4 of 11 patients (36%) in GB showed recurrent tumor at remote regions which were different from residual tumor. Conclusions: The present study suggested that met-PET is beneficial to decide to discontinue adjuvant chemotherapy with TMZ in patients with residual tumors of DA and AA, but not useful for patients with GB. Reasons for unsuccessful results in GB might have been small sample size, failure of establishing the cut off value in T/N, recurrences at remote regions where not be assessed by met-PET.

Estilos ABNT, Harvard, Vancouver, APA, etc.

Pettiwala, Aafrin M., Cathy Pichol-Thievend, Oceane Anezo, Guillaume Bourmeau, Remi Montagne, Anne-Marie Lyne, Pierre-Olivier Guichet Guichet et al. "TMIC-76. GLIOBLASTOMA VESSEL CO-OPTION OCCURS AS A RESISTANCE MECHANISM TO CHEMORADIATION VIA INDUCTION OF A NOVEL CELL STATE". Neuro-Oncology 25, Supplement_5 (1 de novembro de 2023): v295. http://dx.doi.org/10.1093/neuonc/noad179.1141.

Texto completo da fonte

Resumo:

Abstract Glioblastoma (GB) is one of the deadliest types of human cancer. Despite a very aggressive treatment regime-including resection, chemo-radiation, its recurrence rate is more than 90%. Recurrence is mostly caused by highly resistant and invasive cells that spread from tumor bulk and are not removed by resection. To develop an effective therapeutic approach, we need to better understand underlying molecular and cellular mechanism driving therapy resistance and invasion in GB. To dynamically track the changes post-therapy and chemoradiation-resistant cells, we employed multiple bulk and single cell transcriptomics, phosphoproteome, in vitro and in vivo real time imaging, organotypic cultures, functional analysis, digital pathology and spatial transcriptomics on patient material and preclinical models of GB. We demonstrated that the chemoradiation and brain vasculature induce a transition to invasive functional cell state, which we rename as VC-Resist. Better cell survival, G2M arrest, senescence/stemness pathway induction, makes this GB state much more resistant. Notably, these GB cells are highly vessel co-opting allowing homing to perivascular niche, which in turn increases their transition to this cell state. Molecularly, the transition to VC-Resist cell state takes place through FGF-FGFR1 signaling that leads to activation of DNA damage repair, YAP and Rho pathways. These findings demonstrate that the perivascular niche and GB cell plasticity jointly generates a vicious loop that leads to resistance and brain infiltration during GB recurrence.

Estilos ABNT, Harvard, Vancouver, APA, etc.

Lee, Jae-Myeong, Bong-Wan Kim, Wook Hwan Kim, Hee-Jung Wang e Myung Wook Kim. "Clinical Implication of Bile Spillage in Patients Undergoing Laparoscopic Cholecystectomy for Gallbladder Cancer". American Surgeon 77, n.º 6 (junho de 2011): 697–701. http://dx.doi.org/10.1177/000313481107700623.

Texto completo da fonte

Resumo:

We determined the influence of bile spillage on recurrence and survival during laparoscopic cholecystectomy (LC) for gallbladder (GB) cancer. Among the 136 patients with GB cancer treated at Ajou University Hospital between 1994 and 2007, 28 underwent LC alone. We compared patients without bile spillage (bile spillage [-] group, n = 16) with patients who had bile spillage (bile spillage [+] group, n = 12). There was no statistical difference in stage between the groups. In the bile spillage (-) group, all patients underwent curative resection and there were two patients with locoregional recurrences and three patients with systemic recurrences. In the bile spillage (+) group, five patients underwent R1 resection and one patient underwent R2 resection and all eight recurrent patients had systemic recurrences. The disease-free survival and overall survival were shorter in the bile spillage (+) group (disease-free survival, 71.4 vs 20.9 months; P = 0.028; overall survival, 72.6 vs 25.8 months; P = 0.014). Bile spillage is likely to be an association with an incomplete resection and systemic recurrences. When GB cancer is suspected during LC, conversion to open surgery for preventing bile spillage and achieving curative resection should be considered.

Estilos ABNT, Harvard, Vancouver, APA, etc.

Belokon, S. V., I. A. Gulidov, D. V. Gogolin, K. E. Medvedeva, S. A. Ivanov e A. D. Kaprin. "Re-irradiation combined with bevacizumab in the treatment of glioblastoma recurrence". Siberian journal of oncology 23, n.º 1 (21 de março de 2024): 142–54. http://dx.doi.org/10.21294/1814-4861-2024-23-1-142-154.

Texto completo da fonte

Resumo:

Background. Glioblastoma (GB) remains an aggressive disease with a poor prognosis. despite a comprehensive approach to the treatment of the primary disease, recurrence is almost inevitable. There is still no standard of care for GB recurrence, and many guidelines recommend treating these patients within clinical trials. There are various treatment options available. They include surgery, radiation therapy, systemic or regional chemotherapy or targeted therapy, various immunotherapy strategies, low- and medium-frequency electric fields, and their combinations. The combination of two non-invasive techniques: re-irradiation and systemic targeted therapy remains the most commonly used approach in this group of patients, the potential of which has not been fully realized. The aim of the study was to analyze the literature data on the use of the combination of re-irradiation with bevacizumab as a therapeutic option in patients with GB. Material and Methods. Literature search was performed using Medline, Cochrane Library, E-library, Scopus, PubMed and Google Scholar databases. Results. The current state of the problem was determined, the data available to date on the use of repeated radiotherapy with competitive and/or adjuvant bevacizumab in the treatment of GB recurrence were summarized and analyzed, different regimens of this approach were compared, and the prospects and possible ways of solving the existing problems of this therapeutic option were described. Conclusion. Re-irradiation with concomitant administration of bevacizumab may provide safer treatment of GB recurrence, including large-volume glioblastoma, with acceptable toxicity, in particular radiation necrosis, especially when an appropriate fractionation schedule is used.

Estilos ABNT, Harvard, Vancouver, APA, etc.

Cianci, Francesca, Guido Rey, Dietmar Krex, Davide Ceresa, Paolo Malatesta e Michele Mazzanti. "Abstract 2092: Genomic and proteomic analysis of glioblastoma recurrences during TTFields exposure". Cancer Research 84, n.º 6_Supplement (22 de março de 2024): 2092. http://dx.doi.org/10.1158/1538-7445.am2024-2092.

Texto completo da fonte

Resumo:

Abstract Glioblastoma (GB) is the most aggressive type of brain tumor, and current treatments are generally ineffective in preventing recurrence. Tumor Treating Fields (TTFields) are an innovative treatment that has been shown to improve patients' life expectancy in the last two decades. TTFields therapy has an antitumoral effect that involves different mechanisms and is an optional add-on to standard maintenance temozolomide. Although TTFields therapy initially slows tumor progression, it does not prevent tumor relapse in most patients. In the present investigation, we run a genomic and proteomic analysis of surgical material from 10 patients treated with TTFields. GB tissues were obtained from the primary tumor mass and from a second surgery after tumor relapse. All the patients, in addition to brain tumor standard therapies, were treated with TTFields for eighteen hours a day, the time span of treatment application was dependent on GB recurrence. Control samples were obtained from primary and secondary surgeries of 5 patients treated with standard therapy alone. The GB tissue extracts were analyzed with an RNAseq routine, and the results from the secondary surgery were compared with the data obtained from tumor specimens of the primary surgery. A common feature of transcripts among all the patients was the alterations of several pathways promoting the increase of intracellular oxidation and cell cycle regulation. In parallel with the analysis of patient specimens, we developed an in vitro GB cell relapse model. This was instrumental in investigating the beneficial contribution of TTFields action during tumor relapse, but also in uncovering the limitation of this therapeutic procedure. GB primary cultures obtained from patients' surgery were exposed for up to 12 days with 200 kHz TTFields stimulation using the inovitro™ system. After 12 days of continuous TTFields application, GB cells showed an average depolarization of the resting membrane potential, increasing oxidation, and acidification of the cytoplasm. Genomic analysis of treated cells compared with wild-type primary culture, denoted an increase of tumor stem cell markers, activation of several metabolic pathways, and upregulation of different ion channel protein transcripts. Our final goal is to identify specific molecular features enhanced by TTFields treatment to be used as a parallel therapy to fight GB recurrence. Citation Format: Francesca Cianci, Guido Rey, Dietmar Krex, Davide Ceresa, Paolo Malatesta, Michele Mazzanti. Genomic and proteomic analysis of glioblastoma recurrences during TTFields exposure [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2092.

Estilos ABNT, Harvard, Vancouver, APA, etc.

Simionescu, Natalia, Miruna Nemecz, Anca-Roxana Petrovici, Ioan Sebastian Nechifor, Razvan-Cristian Buga, Marius Gabriel Dabija, Lucian Eva e Adriana Georgescu. "Microvesicles and Microvesicle-Associated microRNAs Reflect Glioblastoma Regression: Microvesicle-Associated miR-625-5p Has Biomarker Potential". International Journal of Molecular Sciences 23, n.º 15 (29 de julho de 2022): 8398. http://dx.doi.org/10.3390/ijms23158398.

Texto completo da fonte

Resumo:

Glioblastoma (GB) is the most aggressive and recurrent form of brain cancer in adults. We hypothesized that the identification of biomarkers such as certain microRNAs (miRNAs) and the circulating microvesicles (MVs) that transport them could be key to establishing GB progression, recurrence and therapeutic response. For this purpose, circulating MVs were isolated from the plasma of GB patients (before and after surgery) and of healthy subjects and characterized by flow cytometry. OpenArray profiling and the individual quantification of selected miRNAs in plasma and MVs was performed, followed by target genes’ prediction and in silico survival analysis. It was found that MVs’ parameters (number, EGFRvIII and EpCAM) decreased after the surgical resection of GB tumors, but the inter-patient variability was high. The expression of miR-106b-5p, miR-486-3p, miR-766-3p and miR-30d-5p in GB patients’ MVs was restored to control-like levels after surgery: miR-106b-5p, miR-486-3p and miR-766-3p were upregulated, while miR-30d-5p levels were downregulated after surgical resection. MiR-625-5p was only identified in MVs isolated from GB patients before surgery and was not detected in plasma. Target prediction and pathway analysis showed that the selected miRNAs regulate genes involved in cancer pathways, including glioma. In conclusion, miR-625-5p shows potential as a biomarker for GB regression or recurrence, but further in-depth studies are needed.

Estilos ABNT, Harvard, Vancouver, APA, etc.

Nakao, Sayumi, Michio Itabashi, Mamiko Ubukata, Yoshiko Bamba, Tomoichiro Hirosawa, Shimpei Ogawa, Shingo Kameoka e Kenichi Sugihara. "Age-specific prognostic factors in patients treated surgically for pulmonary metastases of colorectal cancer: A multi-institutional cumulative follow-up study." Journal of Clinical Oncology 33, n.º 3_suppl (20 de janeiro de 2015): 773. http://dx.doi.org/10.1200/jco.2015.33.3_suppl.773.

Texto completo da fonte

Resumo:

773 Background: The aim of this study was to investigate the age-specific prognostic factors for overall survival (OS) and disease-free interval (DFI) after pulmonary metastasectomy for colorectal cancer (CRC). Methods: We performed a retrospective analysis of 1,179 patients who underwent lung resection for colorectal metastases from 2001 to 2012 in 109 affiliated institutions of the Japanese Society for Cancer of the Colon and Rectum study group. The patients were divided into three groups by the age at pulmonary resection: Group A (GA) comprised of 396 patients who underwent lung resection under the age of 60 years old; Group B (GB) comprised of 604 patients who underwent lung resection between the ages of 61 and 74 years old; Group C (GC) comprised of 179 patients who underwent lung resection over the age of 75 years old. We used the Cox proportional hazard regression to identify independent prognostic factors for OS and DFI. Results: Median OS times after pulmonary resection were 45 months, 43 months, and 43 months for GA, GB, and GC, respectively. Two-year and 5-year overall survival rates were 73% and 54% for GA, 77% and 63% for GB, and 82% and 68% for GC, respectively. The independent unfavorable prognostic factors were recurrence after pulmonary resection (p<0.0001) in GA, detection of liver metastases before lung resection (p=0.0126), a high level of carcinoembryonic antigen (p=0.0003), and recurrence after pulmonary resection (p<0.0001) in GB, and recurrence after pulmonary resection (p<0.0001) in GC. Median DFI times were 11 months in all groups. The independent unfavorable prognostic factor was a removal of mediastinal lymph node (p=0.0335) in GB. Conclusions: Elder patients (GC) showed nearly the same OS rate compared with non-elder patients (GB), while younger patients (GA) showed poor OS rate. Recurrence after pulmonary resection revealed to be a poor prognostic factor in all groups.

Estilos ABNT, Harvard, Vancouver, APA, etc.

Mais fontes

Teses / dissertações sobre o assunto "GB recurrence"

Larrieu, Claire. "Adaptations métaboliques impliquées dans le développement et la rechute des glioblastomes : Etude du rôle du métabolisme du lactate". Electronic Thesis or Diss., Bordeaux, 2024. http://www.theses.fr/2024BORD0060.

Texto completo da fonte

Resumo:

Le glioblastome (GB) est le cancer cérébral le plus fréquent mais aussi le plus agressif chez l’adulte. Outre d’importantes capacités prolifératives et invasives, induisant un mauvais pronostic et un fort taux de rechute, les cellules de GB présentent également une forte plasticité métabolique. En effet, la cohabitation de cellules glycolytiques et oxydatives dans la tumeur participe à l’établissement d’une symbiose métabolique favorisant la survie et la progression des cellules malignes, ainsi que leur échappement aux traitements actuels. Nos travaux ont permis de mettre en évidence cette symbiose métabolique intra-tumorale, centrée sur des échanges de lactate entre la population de la tumeur centrale et la population invasive. La déstabilisation de ce métabolisme du lactate intra-tumoral, en bloquant l’action d’acteurs impliqués directement, comme les LDHs, ou indirectement, comme les PDHKs, a montré des résultats encourageants en altérant la progression du GB in vitro et in vivo.En clinique, la résection tumorale, lorsqu’elle est possible, est la première intervention thérapeutique chez le patient. Acte traumatique et invasif pour le patient, l’exérèse de la masse tumorale est également traumatique pour la tumeur elle-même puisqu’elle désorganise totalement la symbiose métabolique intra-tumorale. De manière systématique, les cellules invasives ayant échappé à la résection sont capables de basculer vers un phénotype prolifératif pour reformer une tumeur. En effet, le retrait de la masse tumorale, fortement productrice de lactate, entraine des fluctuations de la concentration de ce métabolite dans les cellules résiduelles post-résection. Nos récents résultats montrent que ces fluctuations semblent induire des adaptations métaboliques favorisant survie et prolifération. Conjointement aux protocoles cliniques actuels, le blocage thérapeutique de ces reprogrammations métaboliques pourrait être une approche adaptée pour prévenir les récidives tumorales du GB
Glioblastoma (GB) is the most frequent and most aggressive brain cancer in adult. Additionally to strong proliferative and infiltrative capacities responsible for bad prognosis and frequent relapse, GB cells also exhibit high metabolic plasticity. In fact, glycolytic and oxidative cells live side by side in the tumor and form a metabolic symbiosis supporting survival, progression and resistance to treatment of these malignant cells. Our work show that this intra-tumoral metabolic symbiosis in GB is centered on lactate exchanges between the core tumor and the invasive population spreading in the brain. Disturbing this intra-tumoral lactate metabolism, directly by blocking LDHs or indirectly by targeting regulatory enzymes such as PDHKs, has shown interesting alteration of GB progression in vitro and in vivo.In clinic, surgical resection of the tumor (when possible) is often the first step of therapy for patients with GB. Traumatic and invasive act for patients, resection is also traumatic for the tumor itself, by strongly disturbing intra-tumoral metabolic symbiosis. However, invasive cells escaping this surgical step are invariably switching back to a proliferative phenotype and growing a new tumor. Indeed, surgical removal of tumor mass, the main glycolytic producer of lactate in GB, induces lactate fluctuations also in these post-resection residual GB cells. These fluctuations seem to be responsible for metabolic rewiring sustaining survival and proliferation. Then, adding a metabolic block to the actual standard therapy could be of significant interest to prevent GB progression and relapse

Estilos ABNT, Harvard, Vancouver, APA, etc.

Trabalhos de conferências sobre o assunto "GB recurrence"

Yang, Chuanchuan, Yunfeng Gao, Jiaxing Wang, Hongbin Li e Constance J. Chang-Hasnain. "Enhanced Recurrent Neural Network Equalization based on Hidden Feature Extraction Learning for Optical Interconnect". In Optical Fiber Communication Conference. Washington, D.C.: Optica Publishing Group, 2024. http://dx.doi.org/10.1364/ofc.2024.th3d.1.

Texto completo da fonte

Resumo:

We propose a hidden feature extraction learning method for RNN equalization to improve training efficiency without increasing computational burden. Superior BER is demonstrated in 288 Gb/s 100 m VCSEL-MMF interconnect compared with black-box training strategy.

Estilos ABNT, Harvard, Vancouver, APA, etc.

Wang, Wei, Jiangtao Liu, Xiaolin Lyu, Xin Hu, Yifan Li, Lamia Rouis, Mourad Khdhaouria e Aldrin Rondon. "Application of Deep Learning in First-Break Picking of Shallow OBN Data". In Gas & Oil Technology Showcase and Conference. SPE, 2023. http://dx.doi.org/10.2118/213983-ms.

Texto completo da fonte

Resumo:

Abstract Summary As well known, the modeling of the near-surface from first-break plays a significant role on the sub-surface imaging, reservoir characterization, and monitoring. Small errors in first-break picking can greatly impact the seismic velocity model building, so it is necessary to pick high-quality travel times. Geoscientists from around the world continues trying their best to address the near-surface challenges. Due to the rapid development of high-efficiency acquisition technique, such as WBH (wide-azimuth, broadband and high-density) acquisition technique and blended source acquisition technique, the quantity of seismic data, especially 3D seismic exploration, has leapt from GB to TB(some to PB), which sets a big challenge for first-break picking. Traditional first-break picking methods can't meet the production. In recent years, with the development of computer capacity and algorithm, artificial intelligence has changed our lives in many ways. In seismic exploration, artificial intelligence, like deep learning, has played a more and more important role now, from fault prediction, attribute identification to velocity and first break picking. Generally, deep learning is a new neural network which has multiple hidden layers, mostly over 3 layers, compared with traditional neural network. Deep learning includes Deep Belief Network (DBN), Convolutional Neural Network (CNN), Recurrent Neural Network (RNN) and so on. In this paper, Convolutional Neural Network (CNN) and Recurrent Neural Network (RNN) have been combined for first-break picking in a large 3D OBN project of Caspian Sea. A high precision near seabed velocity model is built based on the auto-picked first break with tomography inversion, which provides a good solution for static problem of the survey.

Estilos ABNT, Harvard, Vancouver, APA, etc.

Xu, Zhaopeng, Chuanbowen Sun, Tonghui Ji, Honglin Ji e William Shieh. "Cascade Recurrent Neural Network Enabled 100-Gb/s PAM4 Short-Reach Optical Link Based on DML". In Optical Fiber Communication Conference. Washington, D.C.: OSA, 2020. http://dx.doi.org/10.1364/ofc.2020.w2a.45.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

Xu, Zhaopeng, Shuangyu Dong, Chenxin Jiang, Jonathan H. Manton e William Shieh. "Sparsely-Connected Cascade Recurrent Neural Network-Based Nonlinear Equalizer for a 100-Gb/s PAM4 Optical Interconnect". In Asia Communications and Photonics Conference. Washington, D.C.: OSA, 2021. http://dx.doi.org/10.1364/acpc.2021.m5h.4.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

Gao, Yunfeng, Chuanchuan Yang, Jiaxing Wang, Xin Qin, Haipeng Guo, Xiaoyu Zhang, Chih-Chiang Shen, Hongbin Li, Zhangyuan Chen e Constance J. Chang-Hasnain. "288 Gb/s 850 nm VCSEL-based Interconnect over 100 m MMF based on Feature-enhanced Recurrent Neural Network". In Optical Fiber Communication Conference. Washington, D.C.: Optica Publishing Group, 2022. http://dx.doi.org/10.1364/ofc.2022.m4h.2.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

Oferecemos descontos em todos os planos premium para autores cujas obras estão incluídas em seleções literárias temáticas. Contate-nos para obter um código promocional único!